ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial
Who is this study for? Patients with renal cell carcinoma
What treatments are being studied? PROSENSE
Status: Active_not_recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This experiment is designed for post marketing data collection of a cryosurgical system \[PROSENSE™ of IceCure Medical\], for the treatment of renal cell carcinoma (RCC).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patient is above 18 years old.
• The patient has enhanced solid mass of renal origin located in the kidney or elsewhere proved by imaging.
• Patient's mass size is up to 5 cm at its largest dimension.
• Patient is able to visit the clinic as needed during the 60-month follow-up period following the cryoablation procedure.
• The patient has been informed of the study and agrees to its provisions, and has signed an IRB approved written informed consent, including data privacy authorization.
Locations
Other Locations
Israel
Bnei Zion Medical Center
Haifa
Shamir Medical Center
Ẕerifin
Time Frame
Start Date: 2014-07
Completion Date: 2026-02
Participants
Target number of participants: 120
Treatments
Other: single arm, open label, treatment
single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance
Authors
Related Therapeutic Areas
Sponsors
Collaborators: Assaf-Harofeh Medical Center, Bnai Zion Medical Center
Leads: IceCure Medical Ltd.